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Respiratory infection with Bordetella pertussis leads to severe effects in the lungs. The resulting immunity and also immunization
with pertussis vaccines protect against disease, but the induced type of immunity and longevity of the response are distinct. In this
study the effects of priming, by either vaccination or infection, on a subsequent pathogen encounter were studied. To that end,
three postchallenge transcriptome datasets of previously primed mice were combined and compared to the responses in unprimed
control mice. In total, 205 genes showed different transcription activity. A coexpression network analysis assembled these genes
into 27 clusters, combined into six groups with overlapping biological function. Local pulmonary immunity was only present in
mice with infection-induced immunity. Complement-mediated responses were more prominent in mice immunized with an outer
membrane vesicle pertussis vaccine than in mice that received a whole-cell pertussis vaccine. Additionally, 46 genes encoding for
secreted proteinsmay serve asmarkers in blood for the degree of protection (Cxcl9, Gp2, andPla2g2d), intensity of infection (Retnla,
Saa3, Il6, and Il1b), or adaptive recall responses (Ighg, C1qb). The molecular signatures elucidated in this study contribute to better
understanding of functional interactions in challenge-induced responses in relation to pertussis immunity.
1. Introduction
Whooping cough, caused by Bordetella pertussis, is an
endemic disease with considerable health impact [1, 2]. Sev-
eral vaccines against B. pertussis aremarketed or under devel-
opment. These include whole-cell pertussis vaccine (wPV),
acellular pertussis vaccine (aPV), live-attenuated pertussis
vaccine (BPZE1), and vaccines based on outer membrane
vesicles (omvPV) [3–6].These vaccines are very differentwith
regard to concept (whole-cell inactivated, subunit, live atten-
uated), composition, and route of immunization. Although
all vaccines confer protection in the mouse challenge model
[3–6], the type and level of immunity are different [3–6].This
difference in immunity leads to distinct pulmonary immune
responses upon subsequent B. pertussis encounter [7, 8].
Analysis of different transcriptome datasets is a tool for
unbiased investigation of biological processes. It has been
used to compare, for instance, the immune responses induced
by different vaccines to identify universal vaccine-induced
signatures [9–11]. Previously, differences in pulmonary gene
expression of mice immunized with omvPV or wPV [8]
and mice receiving a primary infection [7] were elucidated.
However, the pulmonary transcriptome datasets obtained by
challenge experiments may contain potential gene markers
related to pertussis immunity. The identification of those
markers may contribute to better understanding of pertussis
immunity and as readout in a human challenge model [12].
We performed a meta-analysis of pulmonary transcrip-
tome datasets obtained after a B. pertussis challenge in mice
with a different pertussis immune status.These includedmice
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with infection-induced immunity, wPV-immunized mice
(wPV-mice), omvPV-immunized mice (omvPV-mice), and
nonimmunized mice (NI mice) as control [7, 8]. The molec-
ular signatures were characterized with special attention for
secreted proteins, since these markers could potentially be
useful for monitoring immune responses in blood samples
to determine degree of protection, intensity of infection, or
promptness of adaptive recall responses for later application
in human challenge studies.
2. Methods
2.1. Datasets. We used gene expression datasets from four
B. pertussis challenge experiments in BALB/c mice. These
included data from challenge studies performed 56 days
after the primary immunization or infection [7, 8]. We
includedmicewith (i) infection-induced immunity following
a single infection with 2 × 105 colony forming units of a B.
pertussis B1917 strain, mice immunized twice with 4𝜇g total
protein of (ii) wPV or (iii) omvPV, and (iv) nonimmunized
mice (Figure 1(a)).The lung colonization data was previously
obtained and described for unprimed mice and mice with
infection-induced immunity [13] and mice immunized with
wPV and omvPV [8].
2.2. Gene Expression Analysis. The flow diagram showing
all stages of the gene expression analysis and the selection
criteria is shown in Figure 1(b). For all datasets, we included
five time points: 56 days postprimary infection (p.i.) or
immunization, but before challenge (D0), and 4 hours, 2
days, 7 days, and 14 days postintranasal B. pertussis chal-
lenge (p.c.). Gene expression profiles of nonchallenged and
nonimmunized mice were used as a control. In each of the
four experiments, differentially expressed genes (DEGs) were
identified by using previously described methods [13, 14],
namely, a one-way ANOVA at a stringency value of 𝑝 <
0.001 and an absolute Fold Ratio (FR, i.e., challenge response
to the control group) ≥ 2.0. Data for the combined set
of DEGs (across time points in one study) were merged.
This set of DEGs was further refined by (i) identifying
DEGs that differed by a fold change ≥ 2.0 across studies at
one time point; (ii) excluding genes that are not protein-
coding (mainly genes annotated by NCBI as “gene model” or
“hypothetical gene”); and (iii) excluding genes with batch-to-
batch variation between arrays in the control groups.
2.3. Functional Analysis. For the resulting datasets, a coex-
pression network was created, based on the Euclidean dis-
tance between their overall response patterns across all
groups and time points. Genes were connected in a network
if their coexpression similarity fell in the top 1% of overall
most similar responses. Additionally, remaining genes were
connected to genes with the most similar response over
time in order to include each gene in the network. Further
functional analysis and identification of genes that encode for
secreted proteins based on the Uniprot-term “secreted” were
performed by using DAVID [15].
2.4. Data Visualization. Data were visualized using Adobe
Illustrator CC 2015, Cytoscape (version 2.8.3) (http://www
.cytoscape.org), R (https://www.r-project.org), Genemaths
XT (AppliedMaths, St-Martens-Latem, Belgium), andVenny
(http://bioinfogp.cnb.csic.es/tools/venny/index.html).
3. Results and Discussion
3.1. Identification of Gene Expression Signature Clusters. The
pulmonary transcriptomes of four individual B. pertussis
challenge experiments were merged. The immunization and
B. pertussis challenge scheme of these studies is shown in
Figure 1(a). Individual datasets revealed 975 DEGs (FR ≥ 2.0,
p ≤ 0.001) in one or more datasets (Figure 2). In total, 627,
256, 169, and 280 genes were included in the nonimmunized,
omvPV-immunized, and wPV-immunized mice and mice
with infection-induced immunity, respectively. Subsequently,
we identified DEGs (FR ≥ 2.0, p ≤ 0.001) between the datasets
for each time point. This second round of identifying DEGs
between studies, combined with a “cleanup” by exclusion
of functionally less relevant genes, that is, hypothetical or
nonprotein-coding genes (Figure 1), left 205 genes for fur-
ther analysis (Table 1). Coexpression patterns for these 205
genes were determined and visualized in a network analysis
(Figure 3). This analysis split the 205 genes into 27 signature
clusters (A–AA) ranging in size from 2 to 75 genes (Table 1).
The average gene expression was calculated for each gene
cluster and visualized in a heatmap (Figure 4).
3.2. Function of Clusters and Relation to Pertussis-Vaccinated
Background. To determine the function of the individual
clusters, an overrepresentation analysis was performed using
DAVID. The different clusters were combined to six groups
with overarching biological functions (group I–VI) (Figures
3 and 4). From these molecular signatures, we additionally
identified the genes that encode for secreted proteins. Because
they may serve as markers that can be analyzed in blood
and could be interesting candidates for later application in
human studies. In total, 46 genes were identified to code for
secreted proteins, which were present in the different groups,
except for group III (Figure 5). Gene expression of clusters
and single genes were compared with the number of colony
forming units (cfu) in the lung (Figures 4 and 5) which were
determined previously in primed and unprimed mice [7, 8].
At this point, we are able to isolate different molecular
signatures from this analysis based on the gene expression
kinetics: first, (i) signatures of local immunity induced by
the primary vaccination or infection that are still active or
present in the lungs on D0, just before challenge; second, (ii)
signatures of infection intensity (the NImice have the highest
number of bacteria in the lungs on 7 days p.i. whereas these
are cleared faster in primedmice (Figures 4 and 5); therefore,
the kinetics and/or intensity of gene expression of acute
phase and proinflammatory proteins that are secreted during
colonization could indicate the intensity of infection in the
mouse model); finally, (iii) signatures of recall responses of
adaptive immunity.These are expressed earlier (within 2 days
p.c.) in immunized mice but are absent or expressed later
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Figure 1: Design and method used in this study. Four transcriptome datasets were included obtained after a B. pertussis challenge in the
lungs of nonimmunized mice, mice with infection-induced immunity, and mice immunized subcutaneously (SC) with omvPV or wPV. (a)
The immunization and challenge scheme of the experiments of these datasets. (b) The different steps of the meta-analysis and criteria used
are described and linked to the figures and tables.
on (7–14 days p.i.) in NI mice. The different, groups (I–VI),
clusters (A–AA), and genes encoding secreted proteins will
be described hereafter.
3.2.1. Group I: Innate Activation. Clusters A–E were com-
bined to group I and comprised genes involved in general
immune responses or related to macrophages and T-cell
activation. These clusters were exclusively upregulated in the
lungs of NI mice and mice with infection-induced immunity
mice 4 hours p.c. Cluster A is the largest cluster, with 75 genes,
and included genes involved in cell activation (Relb, Gadd45g,
Lbp, and Sbno2). Lipopolysaccharide binding protein (Lbp)
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Table 1: Detailed information on the 27 gene clusters.
Clusters Number ofgenes Included genes
I
A 75
Abcf1, Abhd8, Agap3, Amotl2, Arap1, Arhgef40, Atp9a, B4galnt1, Cenpb, Cldn3,
Cnp, Cpsf1, Cyp2s1, D17H6S56E-5, Dctn1, Ddr1, Egln2, Fasn, Flii, Lbp, Gadd45g,
Gclc, Get4, Gpr56, Grn, Gstm1, Hgs, Hspb1, Itga3, Itga7, Itih4, Keap1, Kif1c, Lrp10,
Mgll, Mmrn2, Nfe2l1, Os9, Pard6b, Parm1, Pex14, Piezo1, Pip4k2c, Pkm, Plbd2,
Pnpla2, Por, Ralgds, Rbm19, Relb, Rftn1, Rgp1, Rgs12, Rnh1, Rptor, Rrp1, Rsph1,
Rusc2, Sbno2, Sdc3, Sec61a1, Sema3b, Sh3tc1, Slc3a2, Spint2, Sqstm1, Stab1, Tap2,
Tgm2, Tmbim6, Tnip1, Ucp2, Vars, Vpreb3, Zbtb7a
B 5 Crip2, Hdac5, Isyna1, Lrg1, Plxnb2
C 4 Prpf8, Psap, Psmd3, Shisa5
D 4 Cyba, Ehd1, Mvp, Myh14
E 2 Hadha, Man2b1
II
F 10 Ccl19, Ciita, Cxcl12, Cxcr2, Fam26f, Gm12407, Plbd1, Reg3g, Rrm2, BC048546
G 8 Cd74, H2-Ab1, H2-D1, H2-DMa, H2-Eb1, H2-K1, Nup62-il4i1, Steap4
H 7 Bpifb1, Cp, Cxcl17, Ltf, Prom1, Scgb3a1, Tmc5
I 5 Cdhr1, Clca4, Pglyrp1, Ubd, 4833428L15Rik
III
J 3 Ccar1, Gbp10, Gbp6
K 2 Iigp1, Mki67
L 2 Ccna2, Ckap2
IV
M 10 Basp1, C1qb, Cd177, Cxcl13, Gm9758, Gp2, Pla2g2d, Speer4b, Speer4c, Speer4e
N 6 Ccl20, Ighg, Igj, Igk, Igkv4-59, Igkv8-30
O 5 Igh-VJ558, Ighm, Igkc, Igkv4-53, Pigr
P 4 C3, C4a, C4b, Tnfaip2
Q 4 Ccl8, Cxcl9, Retnla, Saa3
R 4 Cfb, Clca3, Lcn2, Tff2
V
S 14 Ank3, BC117090, Bcl2a1a, Bcl2a1b, Bcl2a1c, Bcl2a1d, Cd209f, Cxcl5, Fpr2, Mmp3,Rorc, Scel, Tspan2, A130040M12Rik
T 7 Chil3, Ear1, Ear10, Ear12, Ear2, Ear3, Rnase2a
U 6 Aif1, H2-Aa, H2-Ea-ps, Ms4a7, S100a4, Serpina3g
V 3 Ccl17, Clec4n, 2900060B14Rik
W 3 Ctss, Fcgr2b, Wfdc17
VI
X 4 Agr2, Cxcl11, Igtp, Timp1
Y 3 Cd14, Cxcl2, Fgg
Z 3 Ccl2, Il1b, Il6
AA 2 Arntl, Lox
is involved in recognition of LPS. Moreover, two integrins
(Itga3, Itga7) were detected in this group, which are cell
membrane proteins but not specific for immune cells.
3.2.2. Group II: Pulmonary Bridging Phase. Clusters F–I are
part of group II that was enriched for antigen processing and
presentation. These clusters were induced 7–14 days p.c. in
NI mice, whereas these clusters were constantly expressed
in mice with infection-induced immunity. Cluster G more
specifically included genes involved in MHC signaling (H2-
Ab1, H2-D1, H2-DMa, H2-Eb1, and H2-K1). Additionally,
group II contains genes coding for proteins that are secreted.
These are expressed earlier in mice with infection-induced
immunity compared to the mice receiving a vaccination
(Cxcl12, Cxcl17, Ccl19, and Pglyrp1) (Figure 5). Cxcl17 is a
mucosal cytokine that attracts lung macrophages [16].
3.2.3. Group III: Cell Cycle and Tissue Remodeling. Group
III comprised genes of clusters J–L, associated with the
cell cycle, which were only upregulated 7–14 days p.c. in
NI mice. This group was marked by high activation of the
cell proliferation marker Mki67. In addition, this group is
comprised of interferon-induced GTPases such as Gbp6 and
Gbp10, which are involved in the innate response to protect
against a bacterial infection [17] and Iigp1. Activation of
these genes solely in NI mice suggests enhanced lung cell
proliferation as a result of lung tissue damage. Therefore, the
absence of this gene expression signature in protected mice
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Figure 2: Venn diagram. The overlap of differentially expressed
genes between four datasets obtained from lungs of mice at different
time points after B. pertussis challenge is depicted.
might indicate less collateral lung damage as a result of a
B. pertussis challenge and, accordingly, suggests that recall
responses of the adaptive immune system are sufficient.
3.2.4. Group IV: Mucosal and Systemic Adaptive Recall
Responses. Clusters M–R were part of group IV of which the
genes encode proteins with immunological functions, such as
immunoglobulins, complement factors, and acute inflamma-
tory proteins. Clusters N-O both contain genes involved in
antibody production. Cluster N is related to IgG production
and more active in the lungs of mice with infection-induced
immunity compared to omvPV- and wPV-immunized mice.
Previously, we showed that pertussis immunization leads
to higher total IgG levels compared to infection [18]. The
higher expression of these genes in the lungs may suggest
that the mice with infection-induced immunity have higher
numbers of lung-resident IgG-producing B-cells, especially
in combination with the coclustering of these genes with
Ccl20 that attracts CCR6+ B-cells.The genes (Pigr, Igh-VJ558)
in cluster O are specifically related to IgA production [19] and
were strongly upregulated in mice with infection-induced
immunity from 4 hours to 14 days p.c. This suggests that
mice with infection-induced immunity have more intense
and faster antibody production in the lungs compared to
subcutaneously immunized mice. This was also shown at the
functional level by the presence of specific-IgA in the lungs
of mice with infection-induced immunity [7] and absence
in wPV-mice and omvPV-mice [8]. Local stimulation of
the immune system might be critical because the induction
of antibody-related genes (Iga, Pigr) and mucosal IgA may
lead to better protection. Cluster P contains three members
of the complement system (C3, C4a, and C4b). Members
of complement systems (C1qb, Cfb, C3, C4a, and C4b)
were expressed most profoundly in the lungs of mice with
infection-induced immunity and to a lesser extent in omvPV-
immunized mice. Interestingly, these genes were hardly
expressed in the lungs of wPV-immunized mice (Figure 5).
This suggests that complement-mediated responses, which
may contribute to clear B. pertussis from the lungs [20],
are more prominent in omvPV-immunized mice. Cluster
Q showed most pronounced expression in NI mice 7–14
days p.c. but was also present in wPV-mice 7 days p.c. In
omvPV-mice and mice with infection-induced immunity,
upregulated expression of cluster Q was observed 2 days p.c.
This cluster included Saa3, part of the acute phase response,
Cxcl9, that attracts CXCR3+ cells, a chemoattractant (Ccl8),
and resistin-like molecule 𝛼 (Retnla) that is important in
lung pathology [21]. Notably, the expression of Saa3 and
Retnla follows the number of cfu in the lungs (Figure 5). Mice
with infection-induced immunity showa limited induction of
gene expression for Saa3 and Retnla, which also peaks early,
already 2 days p.c. In addition, they show the fastest lung
clearance [13]. On the contrary, the wPV-mice and NI mice
showed later andmore intense gene expression in accordance
with prolonged lung clearance. The omvPV-mice revealed
earlier expression compared to wPV-mice and NI mice
conforming to the lower inflammatory responses observed in
omvPV-immunized mice [8]. Both Saa3 and Retnla encode
for secreted proteins (Figure 5) and can therefore serve as a
predictor of infection intensity when measured in blood.
3.2.5. Group V: Vaccine-Primed Innate Responses. Clusters S–
W were part of group V, which included genes associated
with myeloid cells. These clusters were mainly upregulated
in omvPV-mice 4 hours p.c. and in wPV-mice 7 days p.c.
In cluster S, which is moderately expressed in omvPV-mice
and wPV-mice, four members were identified belonging to
the B cell leukemia/lymphoma 2 related proteins (Bcl2a1a,
Bcl2a1b, Bcl2a1c, and Bcl2a1d), a pathogen recognition recep-
tor (Fpr2), a C-type lectin receptor (Cd209f ), and matrix
metallopeptidase 3 (Mmp3). Additionally,Cxcl5, a neutrophil
attractant, was highly expressed before the challenge in the
lungs of omvPV-mice and wPV-mice (Figure 5). Notably,
this cluster also included the retinoic acid receptor- (RAR-)
related orphan receptor C (Rorc) that is essential forTh17 cell
differentiation [22]. Cluster T included five members (Ear1,
Ear2, Ear3, Ear10, and Ear12) of the eosinophil-associated,
ribonuclease A family. Cluster Vwas intensely upregulated in
omvPV-mice 4 hours p.c. It containedCcl17 and dendritic cell
specific Clec4n. Together, these clusters represent an influx or
higher proliferation of myeloid cells and DCs that are most
profound in the omvPV-mice.
3.2.6. Group VI: Inflammation. Finally, cluster X–AA formed
group VI that was enriched for the GO-term inflammatory
response. Cluster Y was mainly upregulated 4 hours p.c. This
was most intense in nonimmunized mice and the lowest in
omvPV-mice.This cluster contained the CD14marker (Cd14)
that is involved in LPS recognition, a neutrophil attractant
(Cxcl2), and fibrinogen (Fgg), which is an important atten-
uator of LPS-mediated responses [23]. Cluster Z included
Ccl2 and the proinflammatory cytokines Il6 and Il1b that
were strongly induced in the NI mice and not in the three
immunized groups. This indicates that previous exposure
to either a vaccine or infection prevents induction of these
proinflammatory markers in the lungs upon a B. pertussis
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Figure 3: Network analysis. The 205 differentially regulated genes formed 27 clusters (A–AA). According to overlap in function, the clusters
were subsequently combined in six groups (I–VI).
challenge. Therefore, the presence of these signatures may
serve as amarker formice being unprotected against pertussis
(Figure 5). Finally, cluster AA was only present in wPV-
immunized mice.
4. Conclusions
This meta-analysis revealed molecular signatures specific for
immune responses against pertussis. The signatures were
measured in the lungs ofmice that were previously exposed to
either pertussis vaccination or infection. Comparison of the
gene expression profiles in the lung of differently treatedmice
revealed the following:
(i) Infection, but not subcutaneous vaccination, leads
to induction of local immunity in the lungs. This
local immunity is characterized by enhanced IgA
production and involvement of “trained” pulmonary
innate cells [7].
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Figure 4: Comparison of pulmonary gene expression profiles following a B. pertussis challenge in mice with different pertussis immunity
background. Averaged fold changes of 27 clusters (A–AA) of infected nonimmunized mice and challenged mice with infection-induced
immunity, omvPV-immunization, or wPV-immunization background are depicted in a time course. Additionally, six groups (I–VI) with
similarity in function are shown. The moment at which the B. pertussis infection or challenge was performed is depicted as well as the log10
number of colony forming units (cfu) for each time point postchallenge as determined previously [7, 8].
(ii) Responses to pertussis challenge in the lungs of
omvPV-mice and wPV-mice were similar in nature,
but the omvPV-mice respond slightly faster.
(iii) Gene expressions of complement-mediated responses
aremore prominent in omvPV-immunizedmice than
in wPV-mice.
(iv) Genes with unknown function (Speer4b, Speer4c, and
Speer4e) were associated with genes with well-known
function (C1qb, Cd177) based on their coexpression,
providing insight into their potential immunological
functions.
(v) Genes of potentially secreted proteins were identified
of which some may serve as markers in blood for
analysis of degree of protection (Cxcl9, Gp2, and
Pla2g2d), intensity of infection (Retnla, Saa3, Il6, and
Il1b), or adaptive recall responses (Ighg, C1qb). This
analysis can be performed by using an ELISA or
multiplex immunoassay and, for instance, applied as
readout in a human challenge model [12].
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